glp-1 agonists cardiovascular diseases in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 Receptor Agonists in Chronic

HFD impairs liver glutathione biosynthesis, vitamin D metabolism genes and genes associated with non-alcoholic fatty liver disease (NAFLD) Genes involved in the GSH biosynthesis pathway were significantly downregulated in the livers of mice fed an HFD compared to those of mice fed a healthy diet (controls) (Fig

Immune System Regulation: Promotes balanced immune activity and inflammation control

Targeting FDX1 by trilobatin to inhibit cuproptosis in doxorubicin-induced cardiotoxicity

3 Results 3.1 Characterization of SBA-15 and SNCDs nanoparticles Functionalized SBA-15 mesoporous silica nanoparticles (MSN) were prepared using an aqueous system that consisted of tetraethyl orthosilicate (TEOS) as the silica precursor and cetyltrimethylammonium bromide (CTAB) as the surfactant, following the methodology described in reference [21]